GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anebulo Pharmaceuticals Inc (NAS:ANEB) » Definitions » ROE %

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) ROE % : -146.69% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Anebulo Pharmaceuticals ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Anebulo Pharmaceuticals's annualized net income for the quarter that ended in Dec. 2023 was $-10.87 Mil. Anebulo Pharmaceuticals's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $7.41 Mil. Therefore, Anebulo Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 was -146.69%.

The historical rank and industry rank for Anebulo Pharmaceuticals's ROE % or its related term are showing as below:

ANEB' s ROE % Range Over the Past 10 Years
Min: -284.85   Med: -91.41   Max: -37.42
Current: -97.37

During the past 4 years, Anebulo Pharmaceuticals's highest ROE % was -37.42%. The lowest was -284.85%. And the median was -91.41%.

ANEB's ROE % is ranked worse than
74.83% of 1359 companies
in the Biotechnology industry
Industry Median: -44.08 vs ANEB: -97.37

Anebulo Pharmaceuticals ROE % Historical Data

The historical data trend for Anebulo Pharmaceuticals's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anebulo Pharmaceuticals ROE % Chart

Anebulo Pharmaceuticals Annual Data
Trend Jun20 Jun21 Jun22 Jun23
ROE %
- -284.85 -37.42 -91.41

Anebulo Pharmaceuticals Quarterly Data
Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -88.40 -78.66 -84.82 -104.84 -146.69

Competitive Comparison of Anebulo Pharmaceuticals's ROE %

For the Biotechnology subindustry, Anebulo Pharmaceuticals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anebulo Pharmaceuticals's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anebulo Pharmaceuticals's ROE % distribution charts can be found below:

* The bar in red indicates where Anebulo Pharmaceuticals's ROE % falls into.



Anebulo Pharmaceuticals ROE % Calculation

Anebulo Pharmaceuticals's annualized ROE % for the fiscal year that ended in Jun. 2023 is calculated as

ROE %=Net Income (A: Jun. 2023 )/( (Total Stockholders Equity (A: Jun. 2022 )+Total Stockholders Equity (A: Jun. 2023 ))/ count )
=-11.732/( (15.067+10.601)/ 2 )
=-11.732/12.834
=-91.41 %

Anebulo Pharmaceuticals's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-10.868/( (8.331+6.487)/ 2 )
=-10.868/7.409
=-146.69 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Anebulo Pharmaceuticals  (NAS:ANEB) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-10.868/7.409
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-10.868 / 0)*(0 / 8.2745)*(8.2745 / 7.409)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.1168
=ROA %*Equity Multiplier
=N/A %*1.1168
=-146.69 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-10.868/7.409
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-10.868 / -10.868) * (-10.868 / -11.04) * (-11.04 / 0) * (0 / 8.2745) * (8.2745 / 7.409)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9844 * N/A % * 0 * 1.1168
=-146.69 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Anebulo Pharmaceuticals ROE % Related Terms

Thank you for viewing the detailed overview of Anebulo Pharmaceuticals's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
1017 Ranch Road 620 South, Suite 107, Lakeway, TX, USA, 78734
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company. It is developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.
Executives
Bimal R. Shah director C/O SPECTRUM PHARMACEUTICALS, 11500 SOUTH EASTER AVENUE, SUITE 240, HENDERSON NV 89052
Richard Anthony Cunningham, director, officer: Chief Executive Officer ONE KENDALL SQUARE, BUILDING 200 SUITE 2, CAMBRIDGE MA 02139
Dan George officer: Chief Financial Officer 1412 62ND STREET, EMERYVILLE CA 94608
Sandra A. Gardiner officer: Acting Chief Financial Officer CUTERA, INC., 3240 BAYSHORE BOULEVARD, BRISBANE CA 94005
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Nathaniel Calloway director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Simon Allen director, officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Aron R. English director, 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Kenneth Lin director PO BOX 1005, LOS ALTOS CA 94022
Karah Herdman Parschauer director 60 LEVERONI COURT, NOVATO CA 94949
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Joseph F. Lawler director, 10 percent owner 2110 RANCH ROAD 620 S, #341732, LAKEWAY TX 78734
Areta Kupchyk director C/O ANEBULO PHARMACEUTICALS, INC., 1415 RANCH ROAD 620 SOUTH, SUITE 201, LAKEWAY TX 78734
Jason Aryeh director 11119 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA CA 92037
22nw, Lp 10 percent owner, other: See Explanation of Response 590 1ST AVE S, UNIT C1, SEATTLE WA 98104

Anebulo Pharmaceuticals (Anebulo Pharmaceuticals) Headlines

From GuruFocus